CN108348608A - 抗5t4抗体和抗体-药物缀合物 - Google Patents
抗5t4抗体和抗体-药物缀合物 Download PDFInfo
- Publication number
- CN108348608A CN108348608A CN201680067751.2A CN201680067751A CN108348608A CN 108348608 A CN108348608 A CN 108348608A CN 201680067751 A CN201680067751 A CN 201680067751A CN 108348608 A CN108348608 A CN 108348608A
- Authority
- CN
- China
- Prior art keywords
- seq
- amino acid
- cdr2
- cdr1
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940049595 antibody-drug conjugate Drugs 0.000 title claims abstract description 100
- 239000000611 antibody drug conjugate Substances 0.000 title claims abstract description 98
- 101000801433 Homo sapiens Trophoblast glycoprotein Proteins 0.000 title abstract 6
- 102100033579 Trophoblast glycoprotein Human genes 0.000 title abstract 6
- 229940127121 immunoconjugate Drugs 0.000 title description 5
- 239000000427 antigen Substances 0.000 claims abstract description 54
- 108091007433 antigens Proteins 0.000 claims abstract description 54
- 102000036639 antigens Human genes 0.000 claims abstract description 54
- 241000282414 Homo sapiens Species 0.000 claims abstract description 29
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 25
- 230000003211 malignant effect Effects 0.000 claims abstract description 8
- 208000014951 hematologic disease Diseases 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims description 62
- 229940079593 drug Drugs 0.000 claims description 54
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 46
- 235000018417 cysteine Nutrition 0.000 claims description 43
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 40
- 239000002253 acid Substances 0.000 claims description 22
- 229910021529 ammonia Inorganic materials 0.000 claims description 20
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 230000001225 therapeutic effect Effects 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 9
- 239000000562 conjugate Substances 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 82
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 230000014509 gene expression Effects 0.000 abstract description 28
- 230000027455 binding Effects 0.000 abstract description 17
- 102000013814 Wnt Human genes 0.000 abstract 1
- 108050003627 Wnt Proteins 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 description 168
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 71
- 210000004027 cell Anatomy 0.000 description 53
- 241000283973 Oryctolagus cuniculus Species 0.000 description 42
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- LMGGOGHEVZMZCU-FGJMKEJPSA-N (2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,7,12-tetrahydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-2-carboxylic acid Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(O)=O)C1 LMGGOGHEVZMZCU-FGJMKEJPSA-N 0.000 description 16
- 241000894007 species Species 0.000 description 13
- 230000000875 corresponding effect Effects 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 230000035772 mutation Effects 0.000 description 9
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 8
- 230000008685 targeting Effects 0.000 description 8
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 239000007853 buffer solution Substances 0.000 description 7
- 230000009260 cross reactivity Effects 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 241000699802 Cricetulus griseus Species 0.000 description 6
- RFQYSAASDBNNDZ-UCGHAGIGSA-N [(1s)-1-(chloromethyl)-3-[6-[(4-hydroxybenzoyl)amino]imidazo[1,2-a]pyridine-2-carbonyl]-9-methyl-1,2-dihydrobenzo[e]indol-5-yl] n-[2-[[4-[[(2s)-5-(carbamoylamino)-2-[[(2s)-2-[2-[2-(2,5-dioxopyrrol-1-yl)ethoxy]ethoxycarbonylamino]-3-methylbutanoyl]amino]pe Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=O)C(=O)NC=1C=CC(COC(=O)N(C)CCN(CCOCCO)C(=O)OC=2C3=CC=CC(C)=C3C=3[C@H](CCl)CN(C=3C=2)C(=O)C=2N=C3C=CC(NC(=O)C=4C=CC(O)=CC=4)=CN3C=2)=CC=1)C(=O)OCCOCCN1C(=O)C=CC1=O RFQYSAASDBNNDZ-UCGHAGIGSA-N 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 210000001672 ovary Anatomy 0.000 description 6
- 229910052697 platinum Inorganic materials 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 235000014304 histidine Nutrition 0.000 description 5
- 125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 150000003625 trehaloses Chemical class 0.000 description 5
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 101150073309 Ces1c gene Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 229940122803 Vinca alkaloid Drugs 0.000 description 3
- 230000001399 anti-metabolic effect Effects 0.000 description 3
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 3
- 229930195731 calicheamicin Natural products 0.000 description 3
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 3
- 229960004562 carboplatin Drugs 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 3
- 229960005277 gemcitabine Drugs 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 3
- 229960002066 vinorelbine Drugs 0.000 description 3
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 description 2
- DLKUYSQUHXBYPB-NSSHGSRYSA-N (2s,4r)-4-[[2-[(1r,3r)-1-acetyloxy-4-methyl-3-[3-methylbutanoyloxymethyl-[(2s,3s)-3-methyl-2-[[(2r)-1-methylpiperidine-2-carbonyl]amino]pentanoyl]amino]pentyl]-1,3-thiazole-4-carbonyl]amino]-2-methyl-5-(4-methylphenyl)pentanoic acid Chemical compound N([C@@H]([C@@H](C)CC)C(=O)N(COC(=O)CC(C)C)[C@H](C[C@@H](OC(C)=O)C=1SC=C(N=1)C(=O)N[C@H](C[C@H](C)C(O)=O)CC=1C=CC(C)=CC=1)C(C)C)C(=O)[C@H]1CCCCN1C DLKUYSQUHXBYPB-NSSHGSRYSA-N 0.000 description 2
- 101100330723 Arabidopsis thaliana DAR2 gene Proteins 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
- 229940121849 Mitotic inhibitor Drugs 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229940123237 Taxane Drugs 0.000 description 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 2
- 229960001686 afatinib Drugs 0.000 description 2
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 229960001602 ceritinib Drugs 0.000 description 2
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 2
- 229950009793 naptumomab estafenatox Drugs 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical compound C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 235000011008 sodium phosphates Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229960004964 temozolomide Drugs 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000010474 transient expression Effects 0.000 description 2
- 150000003918 triazines Chemical class 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical class [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 229930184737 tubulysin Natural products 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- YCGQPIRMLGEWMW-UHFFFAOYSA-N 1-[1-butyl-4-(3-methoxyphenyl)-2-oxo-1,8-naphthyridin-3-yl]-3-[4-[(dimethylamino)methyl]-2,6-di(propan-2-yl)phenyl]urea;hydrochloride Chemical compound Cl.CC(C)C=1C=C(CN(C)C)C=C(C(C)C)C=1NC(=O)NC=1C(=O)N(CCCC)C2=NC=CC=C2C=1C1=CC=CC(OC)=C1 YCGQPIRMLGEWMW-UHFFFAOYSA-N 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- 101710153593 Albumin A Proteins 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 241001614291 Anoplistes Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 235000016408 Podocarpus macrophyllus Nutrition 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 244000162450 Taxus cuspidata Species 0.000 description 1
- 235000009065 Taxus cuspidata Nutrition 0.000 description 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- HSRXSKHRSXRCFC-WDSKDSINSA-N Val-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(O)=O HSRXSKHRSXRCFC-WDSKDSINSA-N 0.000 description 1
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 1
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 1
- NLMBVBUNULOTNS-HOKPPMCLSA-N [4-[[(2s)-5-(carbamoylamino)-2-[[(2s)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl n-[(2s)-1-[[(2s)-1-[[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-o Chemical compound C1([C@H](O)[C@@H](C)NC(=O)[C@H](C)[C@@H](OC)[C@@H]2CCCN2C(=O)C[C@H]([C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCC=2C=CC(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN3C(C=CC3=O)=O)C(C)C)=CC=2)C(C)C)OC)=CC=CC=C1 NLMBVBUNULOTNS-HOKPPMCLSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229950001537 amatuximab Drugs 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 108010044540 auristatin Proteins 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960005061 crizotinib Drugs 0.000 description 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- -1 cysteine amino acids Chemical class 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960005501 duocarmycin Drugs 0.000 description 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 1
- 229930184221 duocarmycin Natural products 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 125000005179 haloacetyl group Chemical group 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229950001474 maitansine Drugs 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960005558 mertansine Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229940087004 mustargen Drugs 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-L pemetrexed(2-) Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-L 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229960002633 ramucirumab Drugs 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical class [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- WSTYNZDAOAEEKG-GWJSGULQSA-N tingenone Chemical class CC1=C(O)C(=O)C=C2[C@@](CC[C@]3([C@@H]4C[C@H](C(C[C@@]4(CC[C@@]33C)C)=O)C)C)(C)C3=CC=C21 WSTYNZDAOAEEKG-GWJSGULQSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical group C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
- A61K47/546—Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本公开内容涉及靶向5T4癌胚抗原(TPBG、5T4、Wnt激活抑制因子1(WAIF1))的CDR限定之抗体,其对人5T4抗原表现出与其对食蟹猴5T4的亲和力相同数量级的结合亲和力。要求保护抗体‑药物缀合物(ADC)及其在治疗人实体瘤和恶性血液病中的用途。
Description
技术领域
本发明涉及针对5T4(癌胚)抗原的抗体和相应的抗体-药物缀合物(antibody-drug conjugate,ADC)。
背景技术
5T4癌胚抗原是由针对来自人胎盘合体滋养层微绒毛膜的麦胚凝集素分离的糖蛋白产生的单克隆抗体定义的72kDa糖蛋白。这种单克隆抗体(monoclonal antibody,mAb)在WO89/07947中被命名为5T4。尽管5T4抗原在正常组织中具有有限的表达,但其被多种类型的癌细胞(过)表达。这使得5T4抗原成为特异性癌症靶标以及潜在且有希望的治疗靶标。然而,虽然该靶标发现于在八十年代后期,但仍没有可用的经批准的治疗性抗体。
WO2006/031653公开了原始的mAb 5T4(即,H8)及其人源化形式,二者对体内临床前(毒性)研究中通常使用的多种非人动物物种没有交叉反应性。这些临床前研究旨在确定用于人中的后续剂量递增方案的初始安全剂量;确定为可逆或不可逆毒性作用的潜在靶标的健康组织或器官;以及确定用于临床监测的安全性参数。对于生物药物(例如单克隆抗体),监管指南要求在至少一种相关物种中进行测试(例如,ICH S6监管指南)。在单克隆抗体与物种没有交叉反应性并因此在所述物种中效力不足的情况下,该物种是不相关的。在这样的情况下,可使用替代动物模型,例如经遗传修饰的物种。然而,这将需要大量努力,不仅要开发模型,而且还要能够向监管当局提供可接受的科学理由。
WO2007/106744公开了抗5T4抗体A1、A2和A3,但是,尽管这三种抗体对非人动物物种(例如食蟹猴(cynomolgus monkey))表现出一些交叉反应性,但它们对人5T4的亲和力远低于H8对人5T4的亲和力。
在WO2007/106744第73页公开了通过4-(4’-乙酰基苯氧基)-丁酸连接至加利车霉素(calicheamicin)的抗5T4抗体H8、A1、A2和A3。WO2012/131527公开了连接至马来酰亚胺基己酸-单甲基奥瑞斯他汀F(maleimidocapronic-monomethylauristatin F)的A1(A1-mc-MMAF)。
只有少数靶向5T4抗原的治疗达到临床试验阶段。编码5T4抗原的经修饰牛痘病毒Ankara(MVA)载体的疫苗诱导针对5T4抗原的内源性抗体应答,但其关于转移性肾癌的III期研究未能满足其提高存活的主要终点。另一个实例是naptumomab estafenatox,其为与经修饰葡萄球菌肠毒素E缀合的mAb 5T4 Fab片段。认为该缀合物在肿瘤附近激活T细胞应答。然而,在晚期肾细胞癌中进行的naptumomab estafenatox加IFN-α相对于IFN-α的随机II/III期研究并未满足其延长存活的主要终点。最近也中断了评价A1-mc-MMAF ADC的临床开发。最近,在US和EU临床试验登记中没有列出进行中的临床试验。
WO 2015/155345公开了新的抗5T4抗体和相应的ADC,其中抗5T4抗体(位点特异性地)连接至吡咯并苯并二氮(PDB)二聚体或连接至微管溶素(tubulysin)。但是,尚无可用的临床数据。
以上得出的结论是临床测试的5T4靶向治疗,即抗体、抗体-药物缀合物和疫苗无法达到癌症治疗剂的要求。因此,需要用于癌症治疗的针对5T4抗原的新抗体和相应抗体-药物缀合物。为了确定这些抗体和相应ADC在临床前环境中的适用性,这样的抗体对于与药物候选物的临床前开发相关的非人动物物种的5T4抗原应具有交叉反应性。
发明简述
本发明涉及适合在临床试验中测试的针对人5T4癌胚抗原的抗体及相应的ADC。在临床前环境中合适的抗体和相应ADC对于与药物候选物的临床前开发相关的非人动物物种的5T4抗原应具有交叉反应性。
优选地,抗体对人和食蟹猴具有交叉反应性,并且对人5T4抗原(hu 5T4)表现出与其对食蟹猴5T4抗原(cyno 5T4)的亲和力相同数量级的亲和力。
本发明还涉及所述抗体和相应ADC在治疗实体瘤(solid tumor)和恶性血液病(haematological malignancy)中的用途。
附图简述
图1示出了嵌合mAb、具有HC-41C突变的人源化mAb以及相应的抗5T4 ADC与表达hu5T4的CHO细胞(CHOZN)的结合相对于H8和A1的结合(图1A为克隆789,图1B为克隆833,图1C为克隆825)。
图2示出了嵌合mAb、具有HC-41C突变的人源化mAb以及相应的抗5T4 ADC与表达cyno 5T4的CHO细胞(CHOZN)的结合相对于H8和A1的结合(图2A为克隆789,图2B为克隆833,图2C为克隆825)。
图3示出了抗5T4 ADC 833a-、833b-、833c-、833d-、825a-、825c-vc-seco-DUBA相对于H8-vc-seco-DUBA和非结合对照利妥昔单抗-vc-seco-DUBA在免疫缺陷小鼠中的5T4-阳性BT474细胞系异种移植物中的体内效力。
发明详述
尽管5T4癌胚抗原在正常组织中具有有限的表达,但其被多种癌细胞(过)表达,因此使得5T4抗原成为特异性癌症靶标以及潜在且有希望的治疗靶标。然而,虽然该靶标发现于八十年代后期,但目前还没有针对该靶标的的经批准的治疗剂。
本发明涉及对cyno 5T4抗原具有交叉反应性且对hu 5T4抗原也显示出良好亲和力的针对5T4抗原的抗体和相应的抗体-药物缀合物(ADC)。根据本发明的抗5T4抗体和ADC对cyno 5T4抗原表现出与其对hu 5T4的亲和力相同数量级的亲和力。术语“相同数量级”意指对hu 5T4抗原和cyno 5T4抗原的亲和力彼此相差小于10倍。本发明的抗5T4抗体与现有技术的抗5T4抗体A1和A3相比对hu 5T4抗原具有改善的亲和力,并且与现有技术的抗5T4抗体H8相比对cyno 5T4抗原具有改善的亲和力。亲和力优选使用表达hu 5T4抗原或cyno 5T4抗原的细胞在基于细胞的测定中作为以μg/mL为单位的EC50测量。本发明人在工程化以表达hu 5T4或cyno 5T4的多种细胞(例如MDA-MB-468、PA-1和中国仓鼠卵巢(CHO)细胞)上测量了EC50。本发明的抗体通常显示出低于0.8μg/mL的EC50,该值是使用表达hu 5T4或cyno 5T4抗原的细胞在4℃下用所述抗体孵育细胞30分钟之后测量的。
现有技术抗5T4抗体A1的特征在于来自US8044178的小鼠A1氨基酸序列的重链(HC)可变区(VR)(SEQ ID NO:2,第20-138位)和来自US8044178的小鼠A1氨基酸序列的轻链(LC)VR(SEQ ID NO:4,第21-127位)。现有技术抗5T4抗体A3的特征在于来自US8044178的小鼠A3氨基酸序列的HCVR(SEQ ID NO:10,第20-141位)和来自US8044178的小鼠A3氨基酸序列的LCVR(SEQ ID NO:12,第21-127位)。现有技术抗5T4抗体H8的特征在于SEQ ID NO:52的HCVR和SEQ ID NO:53的LCVR。
本说明书通篇使用的术语“抗体”是指包含两条重链和两条轻链的单克隆抗体(mAb),或其抗原结合片段,例如Fab、Fab′或F(ab′)2片段、单链(single chain,sc)抗体、scFv、单结构域(single domain,sd)抗体、双特异抗体(diabody)或微抗体(minibody)。抗体可以是任何同种型,例如IgG、IgA或IgM抗体。优选地,所述抗体是IgG抗体,更优选IgG1或IgG2抗体。所述抗体可以是嵌合的、人源化的或人的。优选地,本发明的抗体是人源化的。甚至更优选地,所述抗体是人源化或人IgG抗体,最优选人源化或人IgG1 mAb。所述抗体可具有κ(kappa)或λ(lambda)轻链,优选κ(kappa)轻链,即人源化或人IgG1-κ抗体。
在人源化抗体中,HC和LC的可变区中的抗原结合互补决定区(CDR)来源于来自通常为小鼠、大鼠或兔的非人物种的抗体。这些非人CDR可置于HC和LC的可变区的人框架(FR1、FR2、FR3和FR4)内。人FR中的选择的氨基酸可交换为相应的原始非人物种氨基酸以改善结合亲和力,同时保留低免疫原性。或者,原始非人物种FR的选择的氨基酸交换为其相应的人氨基酸以降低免疫原性,同时保留抗体的结合亲和力。将如此人源化的可变区与人恒定区组合。
本发明特别涉及包含选自以下的HCVR CDR和LCVR CDR的抗5T4抗体:
a.SEQ ID NO:1的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:2的CDR1、CDR2和CDR3氨基酸序列;
b.SEQ ID NO:3的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:4的CDR1、CDR2和CDR3氨基酸序列;
c.SEQ ID NO:5的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:6的CDR1、CDR2和CDR3氨基酸序列;
d.SEQ ID NO:7的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:8的CDR1、CDR2和CDR3氨基酸序列;
e.SEQ ID NO:9的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:10的CDR1、CDR2和CDR3氨基酸序列;
f.SEQ ID NO:11的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:12的CDR1、CDR2和CDR3氨基酸序列;
g.SEQ ID NO:13的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:14的CDR1、CDR2和CDR3氨基酸序列;
h.SEQ ID NO:15的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:16的CDR1、CDR2和CDR3氨基酸序列;
i.SEQ ID NO:17的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:18的CDR1、CDR2和CDR3氨基酸序列;
j.SEQ ID NO:19的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:20的CDR1、CDR2和CDR3氨基酸序列;
k.SEQ ID NO:21的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:22的CDR1、CDR2和CDR3氨基酸序列;
1.SEQ ID NO:23的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:24的CDR1、CDR2和CDR3氨基酸序列;
m.SEQ ID NO:25的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:26的CDR1、CDR2和CDR3氨基酸序列;
n.SEQ ID NO:27的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:28的CDR1、CDR2和CDR3氨基酸序列;
o.SEQ ID NO:29的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:30的CDR1、CDR2和CDR3氨基酸序列;
p.SEQ ID NO:31的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:32的CD R1、CDR2和CDR3氨基酸序列;以及
q.SEQ ID NO:33的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:34的CDR1、CDR2和CDR3氨基酸序列。
为了清楚起见,在上文中a至q下列出的抗体的HCVR的CDR1、CDR2和CDR3序列以及LCVR的CDR1、CDR2和CDR3序列在本说明书结尾处给出的序列表中加有下划线。
在一个实施方案中,本发明的抗5T4抗体包含选自以下的HCVR CDR和LCVR CDR:
a.SEQ ID NO:1的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:2的CDR1、CDR2和CDR3氨基酸序列;
b.SEQ ID NO:5的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:6的CDR1、CDR2和CDR3氨基酸序列;
c.SEQ ID NO:11的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:12的CDR1、CDR2和CDR3氨基酸序列;
d.SEQ ID NO:13的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:14的CDR1、CDR2和CDR3氨基酸序列;
e.SEQ ID NO:17的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:18的CDR1、CDR2和CDR3氨基酸序列;以及
f. SEQ ID NO:25的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:26的CDR1、CDR2和CDR3氨基酸序列。
在一个优选的实施方案中,本发明的抗5T4抗体包含选自以下的HCVR CDR和LCVRCDR:
a.SEQ ID NO:1的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:2的CDR1、CDR2和CDR3氨基酸序列;
b.SEQ ID NO:5的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:6的CDR1、CDR2和CDR3氨基酸序列;以及
c.SEQ ID NO:11的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:12的CDR1、CDR2和CDR3氨基酸序列。
在一个更优选的实施方案中,本发明的抗5T4抗体包含选自以下的HCVR CDR和LCVR CDR:
a.SEQ ID NO:5的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:6的CDR1、CDR2和CDR3氨基酸序列;以及
b.SEQ ID NO:11的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:12的CDR1、CDR2和CDR3氨基酸序列。
在另一个实施方案中,本发明涉及包含选自以下的HCVR和LCVR的人源化抗5T4抗体:
a.SEQ ID NO:35的HCVR氨基酸序列和SEQ ID NO:45的LCVR氨基酸序列;
b.SEQ ID NO:36的HCVR氨基酸序列和SEQ ID NO:45的LCVR氨基酸序列;
c.SEQ ID NO:37的HCVR氨基酸序列和SEQ ID NO:44的LCVR氨基酸序列;
d.SEQ ID NO:37的HCVR氨基酸序列和SEQ ID NO:46的LCVR氨基酸序列;
e.SEQ ID NO:40的HCVR氨基酸序列和SEQ ID NO:51的LCVR氨基酸序列;
f.SEQ ID NO:41的HCVR氨基酸序列和SEQ ID NO:51的LCVR氨基酸序列;
g.SEQ ID NO:42的HCVR氨基酸序列和SEQ ID NO:49的LCVR氨基酸序列;
h.SEQ ID NO:43的HCVR氨基酸序列和SEQ ID NO:50的LCVR氨基酸序列;
i.SEQ ID NO:38的HCVR氨基酸序列和SEQ ID NO:47的LCVR氨基酸序列;
j.SEQ ID NO:39的HCVR氨基酸序列和SEQ ID NO:47的LCVR氨基酸序列;以及
k.SEQ ID NO:39的HCVR氨基酸序列和SEQ ID NO:48的LCVR氨基酸序列。
在本发明的第一个实施方案中,人源化的抗5T4抗体包含SEQ ID NO:35的HCVR氨基酸序列和SEQ ID NO:45的LCVR氨基酸序列。
在本发明的第二个实施方案中,人源化的抗5T4抗体包含SEQ ID NO:36的HCVR氨基酸序列和SEQ ID NO:45的LCVR氨基酸序列。
在本发明的第三个实施方案中,人源化的抗5T4抗体包含SEQ ID NO:37的HCVR氨基酸序列和SEQ ID NO:44的LCVR氨基酸序列。
在本发明的第四个实施方案中,人源化的抗5T4抗体包含SEQ ID NO:37的HCVR氨基酸序列和SEQ ID NO:46的LCVR氨基酸序列。
在本发明的第五个优选的实施方案中,人源化的抗5T4抗体包含SEQ ID NO:40的HCVR氨基酸序列和SEQ ID NO:51的LCVR氨基酸序列。
在本发明的第六个优选的实施方案中,人源化的抗5T4抗体包含SEQ ID NO:41的HCVR氨基酸序列和SEQ ID NO:51的LCVR氨基酸序列。
在本发明的第七个优选的实施方案中,人源化的抗5T4抗体包含SEQ ID NO:42的HCVR氨基酸序列和SEQ ID NO:49的LCVR氨基酸序列。
在本发明的第八个优选的实施方案中,人源化的抗5T4抗体包含SEQ ID NO:43的HCVR氨基酸序列和SEQ ID NO:50的LCVR氨基酸序列。
在本发明的第九个优选的实施方案中,人源化的抗5T4抗体包含SEQ ID NO:38的HCVR氨基酸序列和SEQ ID NO:47的LCVR氨基酸序列。
在本发明的第十个实施方案中,人源化的抗5T4抗体包含SEQ ID NO:39的HCVR氨基酸序列和SEQ ID NO:47的LCVR氨基酸序列。
在本发明的第十一个优选的实施方案中,人源化的抗5T4抗体包含SEQ ID NO:39的HCVR氨基酸序列和SEQ ID NO:48的LCVR氨基酸序列。
本发明还涉及ADC,其中接头药物与根据本发明的抗5T4抗体缀合。
在一个实施方案中,本发明涉及ADC,其中接头药物通过天然半胱氨酸与根据本发明的抗5T4抗体随机缀合,所述天然半胱氨酸通过链间二硫键的还原释放。
在另一个实施方案中,本发明涉及ADC,其中接头药物通过工程化半胱氨酸与根据本发明的抗5T4抗体位点特异性地缀合(位点特异性ADC)。
在HC或LC中包含至少一个工程化半胱氨酸的抗5T4抗体具有数个优点。包含工程化半胱氨酸的抗体提供了制备位点特异性ADC的机会,可提供与接头药物表现出良好反应性的缀合位置,并且同时具有降低的在抗体之间形成额外的二硫键(导致聚集)或破坏抗体结构的风险。在HC或LC中的特定位置具有工程化半胱氨酸的另一个优点是降低所得ADC之疏水性的作用。
已在所有抗体结构中存在的腔中和附近鉴定了用于接头药物附接的多个合适的缀合位置,即,在这些位置处的工程化半胱氨酸具有良好的可及性,如WO2015/177360中所公开和要求保护的那样。
当接头药物在本文中要求保护的抗5T4抗体的特定位置缀合时,所述接头药物配合在由所述抗体的恒定重链1(CH1)、可变重链(VH)、可变轻链(VL)和恒定轻链(CL)区域形成的Fab腔中。结果,接头药物(大多数毒素/接头药物是疏水的)被屏蔽在抗体周围的水环境之外,且这样的ADC与其中接头药物通过抗体的天然链间二硫键半胱氨酸缀合的ADC相比疏水性更低,与其中接头药物在不同位置位点特异性地缀合的ADC相比疏水性低得多,在后面的情况下,接头药物被迫在抗体外部,即更多地暴露于亲水性水环境。
在本发明的一个优选实施方案中,根据本发明的抗5T4抗体包含在HC可变区FR或LC可变区FR的位置处的至少一个工程化半胱氨酸。如本说明书通篇使用的术语“工程化半胱氨酸”意指用半胱氨酸替代抗体的HC或LC中的非半胱氨酸氨基酸。如本领域技术人员已知的,这可在氨基酸水平或在DNA水平上进行,例如,通过使用定点诱变。优选地,这样的工程化半胱氨酸通过特异性点突变引入,替代原始/亲本抗体中的现有氨基酸。
优选地,所述至少一个工程化半胱氨酸存在于根据本发明的抗5T4抗体的选自HC40、41和89位(根据Kabat编号)以及LC 40和41位(根据Kabat编号)的一个或更多个位置。词语“Kabat编号”是指Kabat,E.A.等,Sequences of Proteins of ImmunologicalInterest,第五版Public Health Service,Naional Institutes of Health,Bethesda,MD.(1991)中的通常用于抗体编辑的HC可变区或LC可变区的编号系统。使用该编号系统,实际的线性氨基酸序列可包含更少或额外的氨基酸,其对应于可变区的FR或CDR的缩短或插入。可通过在抗体序列与“标准”Kabat编号序列的同源性区域比对来确定给定抗体的残基的Kabat编号。
除了上文中公开的包含HCVR CDR和LCVR CDR的抗5T4抗体和包含HCVR和LCVR的人源化抗体之外,本发明还涉及在选自HC 40、41和89位以及LC 40和41位的位置处在HC和/或LC中包含至少一个工程化半胱氨酸的所述抗体。
在一个优选的实施方案中,本发明的抗5T4抗体包含在选自HC 40、41和89位以及LC 40和41位的位置处的至少一个工程化半胱氨酸并且包含选自以下的HCVR CDR和LCVRCDR:
a.SEQ ID NO:1的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:2的CDR1、CDR2和CDR3氨基酸序列;
b.SEQ ID NO:5的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:6的CDR1、CDR2和CDR3氨基酸序列;以及
c.SEQ ID NO:11的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:12的CDR1、CDR2和CDR3氨基酸序列。
在另一个优选的实施方案中,本发明涉及人源化抗5T4抗体,其包含在选自HC 40、41和89位以及LC 40和41位的位置处的至少一个工程化半胱氨酸,并且包含选自以下的HCVR和LCVR:
a.SEQ ID NO:40的HC氨基酸序列和SEQ ID NO:51的LC氨基酸序列;
b.SEQ ID NO:41的HC氨基酸序列和SEQ ID NO:51的LC氨基酸序列;
c.SEQ ID NO:42的HC氨基酸序列和SEQ ID NO:49的LC氨基酸序列;
d.SEQ ID NO:43的HC氨基酸序列和SEQ ID NO:50的LC氨基酸序列;
e.SEQ ID NO:38的HC氨基酸序列和SEQ ID NO:47的LC氨基酸序列;以及
f.SEQ ID NO:39的HC氨基酸序列和SEQ ID NO:48的LC氨基酸序列。
位置HC 40、41和89位以及LC 40和41位位于抗体的可变区FR以及抗体的Fab部分中。
在一个优选的实施方案中,本发明涉及ADC,其中接头药物通过工程化半胱氨酸与根据本发明的抗5T4抗体位点特异性地缀合,所述工程化半胱氨酸在所述抗5T4抗体的选自HC 40、41和89位(根据Kabat编号)以及LC 40和41位(根据Kabat编号)的一个或更多个位置处。
本发明人已出乎意料地发现,与其中接头药物过抗5T4抗体的天然链间二硫键半胱氨酸缀合的常规的ADC相比,本发明的位点特异性地缀合的ADC表现出改善的物理化学、药理学和/或药代动力学特性。
通常避免对抗体可变部分的修饰,因为其可导致抗原结合亲和力的部分或完全丧失。然而,与一般预期相反,发现抗体的HC和LC的FR中的特定残基适合缀合,并且不会导致缀合接头药物之后抗原结合的(显著)降低。在一个特别优选的实施方案中,本发明涉及ADC,其中所述工程化半胱氨酸在所述抗5T4抗体的选自HC 40和41以及LC 40和41(在所述抗体的Fab部分中)的一个或更多个位置。优选地,所述工程化半胱氨酸在位置HC 41或LC40或41,更优选地在HC 41。
如从文献中已知的,肿瘤微环境中的肿瘤相关蛋白酶可在铰链区部分地切割Fc恒定结构域,与Fc部分中的缀合相比,Fab部分中的缀合是优选的。Fc恒定结构域的切割会导致Fc-缀合的接头药物的损失,这继而会导致降低的ADC体内活性。(Fan等Breast CancerRes.2012;14:R116和Brezsky等PNAS 2009;106:17864-17869)。此外,与Fab部分中这些位置的缀合也使得能够使用本文中公开的抗5T4抗体的抗原结合片段。
根据本发明的(位点特异性)ADC具有与裸抗体类似的结合亲和力和优异的体外效力,并且与现有技术已知的5T4-靶向ADC相比具有改善的体内谱。与现有技术的5T4-靶向ADC相比,预期根据本发明的位点特异性ADC在体内将表现出低的非特异性毒性。在本发明的抗5T4 ADC中,接头药物被屏蔽(使ADC对细胞外蛋白酶切割不敏感),因此药物不太可能被过早释放。
根据本发明,在ADC领域中已知的任何接头药物可用于与根据本发明的抗体(位点特异性)缀合,前提是其具有可与天然或工程化半胱氨酸的巯基反应的化学基团,通常是马来酰亚胺或卤代乙酰基。合适的接头药物可包括作为细胞毒性药物的倍癌霉素(duocarmycin)、加利车霉素(calicheamicin)、吡咯并苯并二氮(PBD)二聚体、美登木素生物碱(maytansinoid)或奥瑞他汀(auristatin)衍生物。可根据本发明使用可切割或不可切割的接头药物。优选地,细胞毒性药物是倍癌霉素、美登木素生物碱或奥瑞他汀衍生物。美登木素生物碱药物的合适实例包括DM1和DM4。奥瑞他汀药物的合适实例包括MMAE和MMAF。
这些缩写是本领域技术人员公知的。本领域技术人员已知的合适接头药物的实例包括mc-vc-PAB-MMAE(也缩写为mc-vc-MMAE和vc-MMAE)、mc-MMAF和mc-vc-MMAF。优选地,所使用的接头是包含缬氨酸-瓜氨酸(vc)或缬氨酸-丙氨酸(va)的可切割接头。
下面描述了根据本发明的(位点特异性)vc-MMAEADC和mc-MMAFADC的一般分子结构。
与mAb连接的vc-MMAE的分子结构
与mAb连接的mc-MMAF的分子结构
在一个实施方案中,本发明涉及ADC,其中接头药物包含倍癌霉素衍生物。
倍癌霉素首次分离自链霉菌属(Streptomyces)物种的培养液,是包含倍癌霉素A、倍癌霉素SA和CC-1065的抗肿瘤抗生素家族的成员。倍癌霉素与DNA的小沟结合并随后引起DNA的不可逆烷基化。这破坏核酸架构,其最终导致肿瘤细胞死亡。
WO2011/133039公开了一系列包含CC-1065的倍癌霉素衍生物的接头药物。根据本发明使用的合适的接头-倍癌霉素衍生物公开于第182至197页。在WO2011/133039的实施例1至12中描述了许多这些接头药物的化学合成。
在一个实施方案中,本发明涉及式(I)的ADC
其中
“抗5T4抗体”是根据本发明的抗5T4抗体,其不具有或具有如本文中所公开的在HC或LC中的至少一个工程化半胱氨酸,
n为0至3,优选0至1,
m代表1至6(优选1至4)的平均DAR,
R1选自
y为1至16,并且
R2选自
在一个优选的实施方案中,式(I)的ADC包含根据本发明的在HC或LC中包含至少一个工程化半胱氨酸的抗5T4抗体,其中所述接头药物通过所述工程化半胱氨酸与所述抗5T4抗体位点特异性地缀合。优选地,所述工程化半胱氨酸在位置HC 40、41或89或LC 40或41,更优选地在HC 41或LC 40或41,最优选地在HC 41。
在本说明书中示出的结构式中,n代表0至3的整数,而m代表1至6的平均药物-抗体比(drug-to-antibody ratio,DAR)。如本领域中公知的,DAR和药物负荷分布可例如通过使用疏水相互作用色谱(HIC)或反相高效液相色谱(RP-HPLC)来确定。HIC特别适用于确定平均DAR。
根据本发明的式(I)的ADC可根据本领域技术人员公知的方法和程序获得。
用于倍癌霉素接头药物的非特异性(随机)缀合(即,与天然半胱氨酸缀合)的合适方法公开于WO2011/133039的实施例15中,而Doronina等Bioconjugate Chem.17(2006):114-124描述了与mc-MMAF的特异性缀合。
用于位点特异性地缀合接头药物的合适方法可例如在以下中找到:WO2005/084390的实施例7和8,其描述了用接头药物vc-MMAE(部分地)负载抗体的完全还原策略;以及WO2006/034488的实施例11和12,其描述了包含美登木素生物碱(DM1)的接头药物的位点特异性缀合。
在一个特定实施方案中,本发明涉及如上文中公开的式(I)的ADC,其中n为0至1,m代表1至6、优选1至4、更优选1至2、甚至更优选1.5至2、最优选1.8至2的平均DAR,
R1选自
y为1至16,优选1至4,以及
R2选自
在一个特定实施方案中,本发明涉及如上文中公开的结构式(I)的ADC,其中n为0至1,m代表1.5至2、优选1.8至2的平均DAR,R1为
y为1至4,并且R2选自
在一个特别优选的实施方案中,本发明涉及式(II)的ADC
其中“抗5T4抗体”是根据本发明的抗5T4抗体,其不具有或具有如本文中所公开的在HC或LC中的至少一个工程化半胱氨酸,且m代表1.5至2、优选1.8至2的平均DAR。
在一个优选的实施方案中,式(II)的ADC包含根据本发明的在HC或LC中包含至少一个工程化半胱氨酸的抗5T4抗体,其中所述接头药物通过所述工程化半胱氨酸与所述抗体位点特异性地缀合。优选地,所述工程化半胱氨酸在位置HC 40、41或89或LC 40或41,更优选地在HC 41或LC 40或41,最优选地在HC 41。
在一个优选的实施方案中,本发明涉及式(II)的ADC,其包含含有选自以下的HCVRCDR和LCVR CDR的抗5T4抗体:
a.SEQ ID NO:1的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:2的CDR1、CDR2和CDR3氨基酸序列;
b.SEQ ID NO:5的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:6的CDR1、CDR2和CDR3氨基酸序列;以及
c.SEQ ID NO:11的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:12的CDR1、CDR2和CDR3氨基酸序列。
在一个更优选的实施方案中,本发明涉及式(II)的ADC,其包含含有选自以下的HCVR和LCVR的人源化抗5T4抗体:
a.SEQ ID NO:40的HC氨基酸序列和SEQ ID NO:51的LC氨基酸序列;
b.SEQ ID NO:41的HC氨基酸序列和SEQ ID NO:51的LC氨基酸序列;
c.SEQ ID NO:42的HC氨基酸序列和SEQ ID NO:49的LC氨基酸序列;
d.SEQ ID NO:43的HC氨基酸序列和SEQ ID NO:50的LC氨基酸序列;
e.SEQ ID NO:38的HC氨基酸序列和SEQ ID NO:47的LC氨基酸序列;以及
f.SEQ ID NO:39的HC氨基酸序列和SEQ ID NO:48的LC氨基酸序列。
在一个甚至更优选的实施方案中,本发明涉及式(II)的ADC,其包含根据本发明的在选自HC 40和41以及LC 40和41的一个或更多个位置处包含至少一个工程化半胱氨酸的抗5T4抗体,其中接头药物通过所述工程化半胱氨酸与所述抗5T4抗体位点特异性地缀合。优选地,所述工程化半胱氨酸在位置HC 41或LC 40或41,最优选地在HC 41。
在一个最优选的实施方案中,本发明涉及式(II)的ADC,其包含含有选自以下的HCVR和LCVR的人源化抗5T4抗体:
a.SEQ ID NO:61的HCVR氨基酸序列和SEQ ID NO:51的LCVR氨基酸序列;
b.SEQ ID NO:62的HCVR氨基酸序列和SEQ ID NO:51的LCVR氨基酸序列;
c.SEQ ID NO:63的HCVR氨基酸序列和SEQ ID NO:49的LCVR氨基酸序列;
d.SEQ ID NO:64的HCVR氨基酸序列和SEQ ID NO:50的LCVR氨基酸序列;
e.SEQ ID NO:59的HCVR氨基酸序列和SEQ ID NO:47的LCVR氨基酸序列;以及
f.SEQ ID NO:60的HCVR氨基酸序列和SEQ ID NO:48的LCVR氨基酸序列;
其中接头药物通过位置HC 41处的工程化半胱氨酸与抗5T4抗体位点特异性地缀合。
本发明还涉及包含如上文中所述的抗5T4抗体或抗5T4 ADC和一种或更多种可药用赋形剂的药物组合物。治疗性蛋白质(例如mAb和(单克隆)ADC)的典型药物制剂采用需要在静脉内输注前(水性)溶解(即,重构)的冻干块(冻干粉末)或者需要在使用前解冻的冷冻(水性)溶液的形式。
通常来说,药物组合物以冻干块的形式提供。用于包含在根据本发明的药物组合物中(在冷冻干燥前)的合适可药用赋形剂包括缓冲溶液(例如在水中的包含柠檬酸盐、组氨酸或琥珀酸盐的盐)、冻干保护剂(例如蔗糖或海藻糖)、张力调节剂(例如氯化钠)、表面活性剂(例如聚山梨酯)和填充剂(bulking agent)(例如甘露醇、甘氨酸)。用于冷冻干燥的蛋白质制剂的赋形剂根据其在冷冻干燥过程期间和在贮藏期间防止蛋白质变性的能力进行选择。作为实例,KadcylaTM(Roche)的无菌冻干粉末单次使用制剂在用抑菌或无菌注射用水(BWFI或SWFI)重构后含有20mg/mL曲妥珠单抗-美坦新偶联物(ado-trastuzumabemtansine)、0.02%w/v聚山梨酯20、10mM琥珀酸钠和6%w/v蔗糖,pH为5.0。
本发明还涉及如上文中所述的抗5T4抗体、ADC或药物组合物,其用作药物。
在一个实施方案中,本发明涉及如上文中所述的抗5T4抗体、ADC或药物组合物,其用于治疗人实体瘤和恶性血液病,优选人实体瘤。
在一个优选的实施方案中,本发明涉及如上文中所述的抗5T4抗体、ADC或药物组合物(特别是包含倍癌霉素衍生物接头药物的ADC),其用于治疗选自乳腺癌、胃癌、结直肠癌、卵巢癌、肺癌(尤其是非小细胞肺癌(NSCLC)和小细胞肺癌(SCLC))和(恶性胸膜)间皮瘤的人实体瘤。
在另一个实施方案中,本发明涉及如上文中所述的抗5T4抗体、ADC或药物组合物(特别是包含倍癌霉素衍生物接头药物的ADC),其用于治疗人恶性血液病,特别是选自急性淋巴细胞白血病和髓性白血病(分别为ALL和AML)的白血病。
本发明还涉及先后或同时施用的如上文中所述的抗5T4抗体、抗5T4 ADC或药物组合物与针对5T4抗原以外的癌症相关靶标的治疗性抗体、化学治疗剂和/或ADC的组合用于治疗如上文中所述的人实体瘤和恶性血液病的用途。
在本发明的一个实施方案中,特别是在包含倍癌霉素衍生物接头药物的抗5T4ADC的情况下,所述治疗性抗体是贝伐单抗、西妥昔单抗、纳武单抗(nivolumab)或雷莫卢单抗(ramucirumab),并且所述化学治疗剂是烷化剂,特别是环磷酰胺、异环磷酰胺或三嗪类,特别是替莫唑胺,或铂类药物,更特别是顺铂或卡铂,抗代谢物类,特别是吉西他滨或培美曲塞,拓扑异构酶II抑制剂,特别是依托泊苷,有丝分裂抑制剂,特别是紫杉烷类,更特别是紫杉醇或多西他赛,或长春花生物碱类,更特别是长春碱或长春瑞滨,或信号级联抑制剂,特别是酪氨酸激酶抑制剂,更特别是伊马替尼、厄洛替尼、色瑞替尼(ceritinib)、克唑替尼(crizotinib)或阿法替尼(afatinib)。
在本发明的另一个实施方案中,特别是在包含倍癌霉素衍生物接头药物的抗5T4ADC的情况下,所述治疗性抗体是贝伐单抗,并且所述化学治疗剂是烷化剂,特别是氮芥,特别是异环磷酰胺或环磷酰胺,铂类药物,特别是顺铂或卡铂,或三嗪类,特别是替莫唑胺,抗肿瘤抗生素,特别是多柔比星,抗代谢物类,特别是吉西他滨,拓扑异构酶I或II抑制剂,特别是拓扑替康、依立替康或依托泊苷,或有丝分裂抑制剂,特别是紫杉烷类,更特别是紫杉醇或多西他赛,或长春花生物碱类,更特别是长春新碱或长春瑞滨。
在本发明的另一个实施方案中,特别是在包含倍癌霉素衍生物接头药物的抗5T4ADC的情况下,所述治疗性抗体是阿马昔单抗(amatuximab),并且所述化学治疗剂是烷化剂,特别是铂类药物,更特别是顺铂或卡铂,抗代谢物类,特别是吉西他滨或培美曲塞,或有丝分裂抑制剂,特别是长春花生物碱,更特别是长春瑞滨。
根据本发明的抗5T4抗体或ADC的治疗有效量为约0.01至约15mg/kg体重,特别地是约0.1至约10mg/kg体重,更特别地是约0.3至约10mg/kg体重。后一范围大致对应于抗体或ADC的20至800mg的固定剂量(flat dose)。本发明的化合物可每周、每两周、每三周、每月或每六周施用。合适的治疗方案取决于疾病的严重程度、患者的年龄、所施用的化合物以及治疗医生会考虑的其他因素。
实施例
免疫接种方案和选择
将兔用hu 5T4/cyno 5T4蛋白质的混合物(2只兔)和MDA-MB-468细胞(2只兔)重复免疫接种。在不同的时间点收集约20mL血液。将单一B细胞沉积在微量滴定板的单个孔中。将这些B细胞在存在条件化培养基和饲养细胞的情况下培养数天。在此期间其产生并将单克隆抗体释放到培养基(B细胞上清液)中。分析这些单一B细胞的上清液的IgG产生,随后确定hu 5T4抗原和cyno 5T4抗原的特异性结合以及与表达5T4的MDA-MB-468细胞的结合。选择了160份B细胞上清液并进行测序,因为这些抗体与人5T4抗原和cyno 5T4抗原二者以及MDA-MB-468细胞结合。获得抗体重链和轻链的131个独特可变区,基因合成并克隆在IgG1亚类的人免疫球蛋白恒定部分上。使用Tecan Freedom Evo平台上的自动化程序,用包含免疫球蛋白序列的质粒瞬时转染HEK 293细胞。在具有板自动进样器的Dionex Ultimate 3000HPLC系统上使用亲和纯化(蛋白A)从细胞上清液中纯化免疫球蛋白。排除了4份生产率非常低的样品,得到总共127种抗体用于重新测试。基于其与人5T4抗原和cyno 5T4抗原的特异性结合以及与表达人5T4的MDA-MB-468细胞的结合来选择抗体。
与hu 5T4和cyno 5T4的结合通过以下程序确定。将hu 5T4抗原或cyno 5T4抗原包被在384-型微量滴定板上。添加参照抗体、B细胞上清液或重组产生的抗体并通过抗兔或人-POD抗体检测结合。
为了与MDA-MB-468细胞的结合,将细胞接种在黑色细胞培养微量滴定板(Coming)上。允许源自B细胞上清液的特异性抗体或参照抗体与细胞相互作用。使用Alexa Fluor48-标记的抗体检测结合。使用CellInsight(Thermo Fischer)装置读取荧光。
选择17种抗体并使用表达人5T4抗原或cyno 5T4抗原的MDA-MB-468细胞、PA-1细胞和中国仓鼠卵巢(CHO)哺乳动物细胞测量对5T4抗原的亲和力(表2)。在本申请中,所使用的CHO细胞被称为CHOZN,因为这些表达人5T4抗原或cyno 5T4抗原的CHO细胞是使用Sigma-Aldrich的Platform获得的。根据制造商的说明书使用Amaxa nucleofector装置(Lonza)瞬时转染CHOZN细胞(SAFC)。使用标准的市售哺乳动物表达载体(SAFC,LifeTechnologies),其包含前面是人CMV启动子的全长人5T4抗原和cyno 5T4抗原编码序列(分别根据登录号NP_006661.1和Q4R8Y9)。在用于抗体结合研究之前,将瞬时转染的CHOZN细胞根据制造商的说明书进行培养。17种选择的抗体由根据下表(表1)的氨基酸序列表征。
表1.嵌合抗5T4单克隆抗体
抗体 | HCVR | LCVR |
789 | SEQ ID NO:1 | SEQ ID NO:2 |
811 | SEQ ID NO:3 | SEQ ID NO:4 |
825 | SEQ ID NO:5 | SEQ ID NO:6 |
828 | SEQ ID NO:7 | SEQ ID NO:8 |
829 | SEQ ID NO:9 | SEQ ID NO:10 |
833 | SEQ ID NO:11 | SEQ ID NO:12 |
834 | SEQ ID NO:13 | SEQ ID NO:14 |
835 | SEQ ID NO:15 | SEQ ID NO:16 |
841 | SEQ ID NO:17 | SEQ ID NO:18 |
843 | SEQ ID NO:19 | SEQ ID NO:20 |
845 | SEQ ID NO:21 | SEQ ID NO:22 |
847 | SEQ ID NO:23 | SEQ ID NO:24 |
848 | SEQ ID NO:25 | SEQ ID NO:26 |
849 | SEQ ID NO:27 | SEQ ID NO:28 |
868 | SEQ ID NO:29 | SEQ ID NO:30 |
899 | SEQ ID NO:31 | SEQ ID NO:32 |
908 | SEQ ID NO:33 | SEQ ID NO:34 |
体外亲和力方案
将表达人5T4抗原或cyno 5T4抗原的MDA-MB-468细胞、PA-1细胞和CHOZN细胞(在96孔板中100,000个细胞/孔)用冰冷的FACS缓冲液(含0.2%v/w BSA(Sigma-Aldrich,St.Louis,MO)的1×PBS(Lonza))和0.02%v/w NaN3(Sigma-Aldrich)洗涤三次,随后添加在冰冷的FACS缓冲液中稀释的浓度范围的每种第一mAb(50μL/孔)。在4℃下孵育30分钟之后,将细胞用冰冷的FACS缓冲液洗涤三次并添加50μL/孔的第二mAb(AffiniPure F(ab’)2片段山羊抗人IgG-APC,1∶6,000稀释,Jackson Immuno Research)。在4℃下30分钟之后,将细胞洗涤两次并重悬于150μL FACS缓冲液中。通过流式细胞术(BD FACSVerse,FanklinLakes,NJ)确定荧光强度并表示为中位荧光强度(median fluorescence intensity,MFI)。在GraphPad Prism(Windows用版本5.01/6.01,GraphPad,San Diego,CA)中使用具有可变斜率的S形剂量-响应方程(四个参数),通过非线性回归拟合曲线。当使用4参数逻辑斯谛拟合(logistic fit)时,将EC50值作为给出在曲线的底部与顶部之间的一半处的响应的以μg/mL为单位的浓度计算。
在表达人5T4抗原(hu 5T4)的MDA-MB-468细胞上测量的嵌合抗体的亲和力为0.040μg/mL至0.730μg/mL的EC50,这与H8的0.19μg/ml的EC50值相当。然而,如在MDA-MB-468细胞上所测量的,A1抗体显示与hu 5T4的较低亲和力的结合(EC50值为4.72μg/ml)。还在表达hu 5T4的PA-1细胞和CHOZN细胞上测量了嵌合抗体对hu 5T4的亲和力。嵌合抗体的EC50值再次与H8的EC50值处于相同的范围内,而A1显示出对hu 5T4的结合亲和力低至少3倍(表2)。在表达hu 5T4的三种细胞类型上A3的EC50值低于相应细胞类型上嵌合抗体的EC50值。
如表2所示,当使用表达hu 5T4的CHOZN或表达cyno 5T4的CHOZN细胞测量时,嵌合抗5T4抗体对hu 5T4和对cyno 5T4具有类似的亲和力。与H8与cyno 5T4的结合相比,除了846(10倍)和828(7倍)之外,大多数嵌合抗体的结合显示出32倍的提高。
表2.表达hu 5T4-和cyno 5T4的细胞上测量的嵌合mAb的亲和力
人源化
通过如下所述的CDR接枝制备人源化抗体。
使用来自编号系统IMGT(LEFRANC,MP,The IMGT unique numbering forimmunoglobulins,T cell receptors and Ig-like domains.The Immunologist,7(1999),第132至136页)和Kabat的CDR定义来鉴定克隆789、825和833的CDR。
使用BLAST检索算法用兔VH结构域检索人IgG序列的在线公共数据库,并从前200个BLAST结果中选择候选人可变结构域。基于例如框架同源性、维持关键框架残基、典型环结构和免疫原性选择了五个候选物。对抗体的VL结构域重复相同的程序。将所有人源化VH变体与所有人源化VL变体组合,得到每种抗体的25种人源化变体。
根据以下程序合成包含HC-41C突变的人源化变体,并且使用表达人5T4或cyno5T4的CHOZN细胞测量其对人5T4和cyno 5T4的亲和力。选择了11种变体进行进一步评价。
抗体的瞬时表达
a)cDNA构建体和表达载体的制备
将来自US8044178的小鼠A1氨基酸序列的HCVR(SEQ ID NO:2,第20至138位)、来自US8044178的小鼠A3氨基酸序列的HCVR(SEQ ID NO:10,第20至141位)和来自SEQ ID NO:52的H8人源化变体1氨基酸序列的HCVR各自在N-末端与HAVT20前导序列(SEQ ID NO:54)连接,并且在C-末端与根据SEQ ID NO:55的人IgG1 HC的恒定结构域连接。将所得到的嵌合氨基酸序列回译成用于在人细胞(人(Homo sapiens))中表达的密码子优化的cDNA序列。
类似地,如下获得构建体的LC的嵌合cDNA序列:连接合适的分泌信号序列(也是HAVT20前导序列)、来自US8044178的小鼠A1氨基酸序列的LCVR(SEQ ID NO:4,第21-127位)、来自US8044178的小鼠A3氨基酸序列的LCVR(SEQ ID NO:12,第21-127位)或H8人源化变体1氨基酸序列SEQ ID NO:53的LCVR、以及人IgG κ轻链恒定区(SEQ ID NO:56),并且将获得的氨基酸序列回译成用于在人细胞(人)中表达的密码子优化的cDNA序列。
使用类似程序获得具有HC-41C突变的人源化变体的LC和HC的cDNA序列,然而,在这种情况下,HC和LC序列在N-末端与兔前导序列(分别为SEQ ID NO:57和58)连接,并且在C-末端与根据SEQ ID NO:55的人IgG1 HC的恒定结构域连接。使用根据下表的序列,根据Kabat编号在HCVR的第41位具有半胱氨酸(表3)。
表3.HC-41人源化变体的HCVR和LCVR
人源化变体 | HCVR | LCVR |
789a | SEQ ID NO:35 | SEQ ID NO:45 |
789b | SEQ ID NO:36 | SEQ ID NO:45 |
789c | SEQ ID NO:37 | SEQ ID NO:44 |
789d | SEQ ID NO:37 | SEQ ID NO:46 |
833a | SEQ ID NO:61 | SEQ ID NO:51 |
833b | SEQ ID NO:62 | SEQ ID NO:51 |
833c | SEQ ID NO:63 | SEQ ID NO:49 |
833d | SEQ ID NO:64 | SEQ ID NO:50 |
825a | SEQ ID NO:59 | SEQ ID NO:47 |
825b | SEQ ID NO:60 | SEQ ID NO:47 |
825c | SEQ ID NO:60 | SEQ ID NO:48 |
b)载体构建与克隆策略
为了表达抗体链,使用市售(Thermo Fisher)哺乳动物表达载体pcDNA3.3的衍生物,其含有CMV:BGHpA表达盒。通过改变CMV启动子下游的多克隆位点以包含AscI和NheI限制性位点来对该载体稍微进行改编,产生表达载体0080pcDNA3.3-SYN。
使用AscI和NheI限制性位点将构建体的HC和LC的cDNA直接连接到0080pcDNA3.3-SYN载体中。将含有HC或LC表达盒的最终载体(分别为CMV:HC:BGHpA和CMV:LC-BGHpA)转移至大肠杆菌NEB 5-α细胞并在其中扩增。使用Maxi-或Megaprep试剂盒(Qiagen)进行用于转染的最终表达载体的大规模生产。
c)在哺乳动物细胞中的瞬时表达
使用ExpiFectamine转染剂根据制造商的说明书如下用表达载体转染市售Expi293F细胞(Thermo Fisher):将75×107个细胞接种到300mL FortiCHO培养基中,将300μg表达载体与800μl ExpiFectamine转染剂组合并添加至细胞。转染之后一天,将1.5mLEnhancer 1和15mL Enhancer2添加至培养物。转染之后六天,通过以4,000g离心15分钟并通过PES瓶过滤器/MF 75过滤器(Nalgene)过滤澄清的收获物来收获细胞培养物上清液。
使用基于细胞的测定的亲和力测量
如在表达hu 5T4或cyno 5T4的CHOZN细胞上测量的,人源化抗5T4抗体对hu 5T4和cyno 5T4具有类似的亲和力,除了825a、825b和825c人源化抗5T4抗体以外,与对hu 5T4相比,其对cyno 5T4的结合低2至3倍(表4)。与H8与cyno 5T4的结合相比,人源化抗5T4抗体的结合提高4至17倍。与A1相比,结合类似地提高。人源化抗5T4抗体对表达hu 5T4的CHOZN细胞的亲和力与H8相当。
表4.在表达hu5T4和cyno5T4的CHOZN细胞上测量的具有HC-41C突变的人源化mAb与一种具有HC-41C突变的嵌合mAb的亲和力
195%CI为95%置信区间
一般位点特异性缀合方案
向半胱氨酸工程化抗5T4抗体溶液(pH 6的4.2mM组氨酸、50mM海藻糖中5至10mg/ml)中添加EDTA(水中25mM,4%v/v)。使用TRIS(水中1M,pH 8)将pH调节至约7.4,然后添加TCEP(水中10mM,20当量)并将所得混合物在室温下孵育1至3小时。使用pH6的4.2mM组氨酸、50mM海藻糖,通过PD-10脱盐柱或Vivaspin离心浓缩器(30kDa截留,PES)除去过量的TCEP。使用TRIS(水中1M,pH 8)将所得抗体溶液的pH升高至约7.4,然后添加脱氢抗坏血酸(水中10mM,20当量),并将所得混合物在室温下孵育1至2小时。添加DMA,随后添加接头药物溶液(DMA中10mM)。DMA的最终浓度为5%至10%。所得混合物在室温下避光孵育1至16小时。为了除去过量的接头药物,添加活性炭并将混合物在室温下孵育1小时。使用0.2μm PES过滤器除去炭并且使用Vivaspin离心浓缩器(30kDa截留,PES)将所得ADC在pH 6的4.2mM组氨酸、50mM海藻糖中配制。最后,使用0.22μm PES过滤器对ADC溶液进行无菌过滤。
用于通过部分地还原的天然链间二硫键半胱氨酸进行缀合的一般(随机)缀合方案(野生型或wt缀合)
向抗5T4抗体溶液(4.2mM组氨酸、50mM海藻糖中5至10mg/ml,pH 6)中添加EDTA(水中25mM,4%v/v)。使用TRIS(水中1M,pH 8)将pH调节至约7.4,然后添加TCEP(水中10mM,取决于抗体和期望的DAR,为1-3当量)并将所得混合物在室温下孵育1至3小时。添加DMA,随后添加接头药物溶液(DMA中10mM)。DMA的最终浓度为5%至10%。所得混合物在室温下避光孵育1至16小时。为了除去过量的接头药物,添加活性炭并将混合物在室温下孵育1小时。使用0.2μm PES过滤器除去炭并且使用Vivaspin离心浓缩器(30kDa截留,PES)将所得ADC配制在4.2mM组氨酸、50mM海藻糖中(pH 6)。最后,使用0.22μmPES过滤器对ADC溶液进行无菌过滤。
使用上述一般程序,合成了基于vc-seco-DUBA(SYD980;即在WO2011/133039第209页的实施例10中的化合物18b,n=1)的半胱氨酸工程化的和野生型ADC,并使用分析型疏水相互作用色谱(HIC)、尺寸排阻色谱(SEC)、屏蔽疏水相色谱(SHPC)、RP-HPLC和LAL内毒素测试进行表征。
对于分析型HIC,将5至10μL样品(1mg/mL)注射到TSKgel Butyl-NPR柱(4.6mm IDx 3.5cm L,Tosoh Bioscience,目录编号14947)上。洗脱方法由以0.4mL/分钟经过20分钟的100%缓冲液A(25mM磷酸钠,1.5M硫酸铵,pH 6.95)至100%缓冲液B(25mM磷酸钠,pH6.95,20%异丙醇)的线性梯度组成。使用配备PDA检测器和Empower软件的Waters AcquityH-Class UPLC系统。在214nm测量吸光度,并确定ADC的保留时间。
通过分析型HIC明显的是,不同半胱氨酸工程化ADC的DAR2物种的保留时间(RT)存在差异。同样,大多数工程化ADC的DAR2物种的RT低于wt H8缀合物的RT(表5),并且对于HC-41C工程化人源化ADC,两种接头药物缀合后保留时间的延长(RTDAR2-RTDAR0)低于对于wt H8-vc-seco-DUBA的延长。所有工程化人源化ADC的RTDAR2-RTDAR0值为2.1至3.1,其低于wt H8-vc-seco-DUBA的RTDAR2-RTDAR0值3.5,表明工程化人源化ADC表现出降低的疏水性。
表5.通过分析性HIC的vc-seco-DUBA ADC的疏水性
1随机(非特异性)附接
体外细胞毒性
如在表达hu 5T4或cyno 5T4的CHOZN细胞上测量的,(位点特异性)抗5T4 ADC的抗原结合亲和力不受附接的倍癌霉素衍生物接头药物的影响(图1和图2)。如所预期,非结合对照ADC(利妥昔单抗vc-seco-DUBA)仅在高浓度时才对表达5T4的肿瘤细胞的生长具有影响。在5T4-阴性人肿瘤细胞系SK-MEL-30(每个细胞约400个5T4抗原结合位点)上,所有人源化抗5T4 ADC无活性(IC50>10nM)。
在表达hu 5T4的MDA-MB-468细胞和PA-1细胞上,工程化人源化抗5T4 ADC的效力与常规缀合的H8-wt ADC的效力相当(表6)。然而,833-ADC系列不能完全降低PA-1细胞活力(效力65%至72%)。此外,工程化人源化抗5T4 ADC比A3-vc-seco-DUBA强效超过2.5倍,并且比A1-vc-seco-DUBA强效超过14倍。
表6.表达5T4的人肿瘤细胞中vc-seco-DUBA ADC的体外细胞毒性
195%CI为95%置信区间
2N/A为不适用
体内效力研究
在B6;D2-Ces1ceFoxn1nu/J小鼠中的BT474(来自60岁白种人女性患者(Caucasianfemale patient)的浸润性导管乳腺癌)细胞系异种移植物模型中评价抗5T4 ADC的体内效力。免疫组织化学染色证实在BT474细胞系的细胞膜上存在hu 5T4。
在用γ-源(2Gy,60Co,BioMep,Dijon,France)全身照射之后24至72小时,通过将200μL含有基质胶(matrigel)的RPMI 1640培养基(50∶50,v∶v)中的2×107个BT-474细胞注射到110只雌性Ceslce裸小鼠的右胁腹来皮下诱导肿瘤。当肿瘤达到200至300mm3的平均体积时,以3mg/kg的H8-、833a-、833b-、833c-、833d-、825a-或825c-vc-seco-DUBA ADC的单次注射对小鼠给药。使用载剂和非结合利妥昔单抗vc-seco-DUBAADC作为对照。分析中排除了血浆中具有Ces1c活性的小鼠。
所有位点特异性地缀合的抗5T4 ADC比现有技术H8-vc-seco-DUBA更大程度减小肿瘤体积(图3),表明改善的体内效力。
体内药代动力学
在B6(Cg)-Ces1ctm1.1Loc/J小鼠品系中用抗5T4 ADC进行药代动力学研究。这些小鼠缺少Ces1c基因的外显子5,导致酶功能的丧失。以抗5T4ADC(3mg/kg,在尾静脉中i.v.)对小鼠给药,并在给药之后0.25、1、6、24、48、96、168、336和504小时收集血浆。使用基于ELISA的测定来定量总抗体和缀合抗体。缀合抗体测定捕获含有至少一种接头药物的ADC物质。表7中示出的结果表明,与现有技术H8-vc-seco-DUBA ADC相比,位点特异性ADC非常稳定,被清除较慢,并且具有更长的半衰期。
表7.抗5T4 ADC在Ces1c Ko小鼠中的药代动力学
总抗体 | 近似t1/2(hr) | Cmax(μg/mL) | AUClast(hr*μg/mL) |
H8-vc-seco-DUBA | nd | nd | nd |
833a-vc-seco-DUBA | 247 | 50.3 | 6484 |
833b-vc-seco-DUBA | 388 | 46.6 | 8702 |
833c-vc-seco-DUBA | 459 | 64.7 | 13177 |
833d-vc-seco-DUBA | nd | nd | nd |
825a-vc-seco-DUBA | 582 | 47.7 | 12596 |
825c-vc-seco-DUBA | 2471 | 74.9 | 20901 |
缀合抗体 | 近似t1/2(hr) | Cmax(μg/mL) | AUClast(hr*μg/mL) |
H8-vc-seco-DUBA | 113 | 54.5 | 3979 |
833a-vc-seco-DUBA | 172 | 61.0 | 4991 |
833b-vc-seco-DUBA | 255 | 56.3 | 8116 |
833c-vc-seco-DUBA | 327 | 52.5 | 8348 |
833d-vc-seco-DUBA | nd | nd | nd |
825a-vc-seco-DUBA | 398 | 67.7 | 11934 |
825c-vc-seco-DUBA | 1049 | 67.2 | 15558 |
nd为未确定
序列表,其中HCVR和LCVR氨基酸序列中的CDR1、CDR2和CDR3氨基酸序列具有下划线
SEQ ID NO:1(克隆/孔789的HCVR-兔)
SEQ ID NO:2(克隆/孔789的LCVR-兔)
SEQ ID NO:3(克隆/孔811的HCVR-兔)
SEQ ID NO:4(克隆/孔811的LCVR-兔)
SEQ ID NO:5(克隆/孔825的HCVR-兔)
SEQ ID NO:6(克隆/孔825的LCVR-兔)
SEQ ID NO:7(克隆/孔828的HCVR-兔)
SEQ ID NO:8(克隆/孔828的LCVR-兔)
SEQ ID NO:9(克隆/孔829的HCVR-兔)
SEQ ID NO:10(克隆/孔829的LCVR-兔)
SEQ ID NO:11(克隆/孔833的HCVR-兔)
SEQ ID NO:12(克隆/孔833的LCVR-兔)
SEQ ID NO:13(克隆/孔834的HCVR-兔)
SEQ ID NO:14(克隆/孔834的LCVR-兔)
SEQ ID NO:15(克隆/孔835的HCVR-兔)
SEQ ID NO:16(克隆/孔835的LCVR-兔)
SEQ ID NO:17(克隆/孔841的HCVR-兔)
SEQ ID NO:18(克隆/孔841的LCVR-兔)
SEQ ID NO:19(克隆/孔843的HCVR-兔)
SEQ ID NO:20(克隆/孔843的LCVR-兔)
SEQ ID NO:21(克隆/孔845的HCVR-兔)
SEQ ID NO:22(克隆/孔845的LCVR-兔)
SEQ ID NO:23(克隆/孔847的HCVR-兔)
SEQ ID NO:24(克隆/孔847的LCVR-兔)
SEQ ID NO:25(克隆/孔848的HCVR-兔)
SEQ ID NO:26(克隆/孔848的LCVR-兔)
SEQ ID NO:27(克隆/孔849的HCVR-兔)
SEQ ID NO:28(克隆/孔849的LCVR-兔)
SEQ ID NO:29(克隆/孔868的HCVR-兔)
SEQ ID NO:30(克隆/孔868的LCVR-兔)
SEQ ID NO:31(克隆/孔899的HCVR-兔)
SEQ ID NO:32(克隆/孔899的LCVR-兔)
SEQ ID NO:33(克隆/孔908的HCVR-兔)
SEQ ID NO:34(克隆/孔908的LCVR-兔)
人源化HCVR氨基酸序列,其中用于半胱氨酸突变的优选第40、41和89位具有下划线
SEQ ID NO:35(HCVR 789人源化形式1)
SEQ ID NO:36(HCVR 789人源化形式2)
SEQ ID NO:37(HCVR 789人源化形式3)
SEQ ID NO:38(HCVR 825人源化形式1)
SEQ ID NO:39(HCVR 825人源化形式2)
SEQ ID NO:40(HCVR833人源化形式1)
SEQ ID NO:41(HCVR 833人源化形式2)
SEQ ID NO:42(HCVR 833人源化形式3)
SEQ ID NO:43(HCVR区833人源化形式4)
人源化HCVR氨基酸序列,其中用于半胱氨酸突变的优选第40和41位具有下划线
SEQ ID NO:44(LCVR 789人源化形式1)
SEQ ID NO:45(LCVR 789人源化形式2)
SEQ ID NO:46(LCVR 789人源化形式3)
SEQ ID NO:47(LCVR 825人源化形式1)
SEQ ID NO:48(LCVR 825人源化形式2)
SEQ ID NO:49(LCVR 833人源化形式1)
SEQ ID NO:50(LCVR 833人源化形式2)
SEQ ID NO:51(LCVR 833人源化形式3)
SEQ ID NO:52(H8 HC)
SEQ ID NO:53(H8 LC)
SEQ ID NO:54(HAVT20前导序列)
1 MACPGFLWAL VISTCLEFSM A
SEQ ID NO:55(人IgG1抗体HC恒定区)
SEQ ID NO:56(人IgG1抗体LCκ恒定区)
SEQ ID NO:57(HC兔前导序列)
1 MGWTLVFLFL LSVTAGVHS
SEQ ID NO:58(LC兔前导序列)
1 MVSSAQFLGL LLLCFQGTRC
人源化HCVR氨基酸序列,其中在根据Kabat编号系统的第41位具有半胱氨酸突变
SEQ ID NO:59(HCVR 825人源化形式1 41C)
SEQ ID NO:60(HCVR 825人源化形式2 41C)
SEQ ID NO:61(HCVR 833人源化形式1 41C)
SEQ ID NO:62(HCVR 833人源化形式2 41C)
SEQ ID NO:63(HCVR 833人源化形式3 41C)
SEQ ID NO:64(HCVR 833人源化形式4 41C)
Claims (16)
1.抗5T4抗体,其包含选自以下的重链(HC)和轻链(LC)可变区(VR)互补决定区(CDR):
a.SEQ ID NO:1的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:2的CDR1、CDR2和CDR3氨基酸序列;
b.SEQ ID NO:3的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:4的CDR1、CDR2和CDR3氨基酸序列;
c.SEQ ID NO:5的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:6的CDR1、CDR2和CDR3氨基酸序列;
d.SEQ ID NO:7的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:8的CDR1、CDR2和CDR3氨基酸序列;
e.SEQ ID NO:9的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:10的CDR1、CDR2和CDR3氨基酸序列;
f.SEQ ID NO:11的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:12的CDR1、CDR2和CDR3氨基酸序列;
g.SEQ ID NO:13的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:14的CDR1、CDR2和CDR3氨基酸序列;
h.SEQ ID NO:15的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:16的CDR1、CDR2和CDR3氨基酸序列;
i.SEQ ID NO:17的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:18的CDR1、CDR2和CDR3氨基酸序列;
j.SEQ ID NO:19的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:20的CDR1、CDR2和CDR3氨基酸序列;
k.SEQ ID NO:21的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:22的CDR1、CDR2和CDR3氨基酸序列;
l.SEQ ID NO:23的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:24的CDR1、CDR2和CDR3氨基酸序列;
m.SEQ ID NO:25的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:26的CDR1、CDR2和CDR3氨基酸序列;
n.SEQ ID NO:27的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:28的CDR1、CDR2和CDR3氨基酸序列;
o.SEQ ID NO:29的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:30的CDR1、CDR2和CDR3氨基酸序列;
p.SEQ ID NO:31的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:32的CD R1、CDR2和CDR3氨基酸序列;以及
q.SEQ ID NO:33的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:34的CDR1、CDR2和CDR3氨基酸序列。
2.根据权利要求1所述的抗体,其包含选自以下的HCVR CDR和LCVR CDR:
a.SEQ ID NO:1的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:2的CDR1、CDR2和CDR3氨基酸序列;
b.SEQ ID NO:5的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:6的CDR1、CDR2和CDR3氨基酸序列;
c.SEQ ID NO:11的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:12的CDR1、CDR2和CDR3氨基酸序列;
其中所述抗体是人源化的。
3.根据权利要求2所述的人源化抗体,其包含
a.SEQ ID NO:1的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:2的CDR1、CDR2和CDR3氨基酸序列以及SEQ ID NO:35的HCVR氨基酸序列和SEQ ID NO:45的LCVR氨基酸序列;
b.SEQ ID NO:1的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:2的CDR1、CDR2和CDR3氨基酸序列以及SEQ ID NO:36的HCVR氨基酸序列和SEQ ID NO:45的LCVR氨基酸序列;
c.SEQ ID NO:1的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:2的CDR1、CDR2和CDR3氨基酸序列以及SEQ ID NO:37的HCVR氨基酸序列和SEQ ID NO:44的LCVR氨基酸序列;
d.SEQ ID NO:1的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:2的CDR1、CDR2和CDR3氨基酸序列以及SEQ ID NO:37的HCVR氨基酸序列和SEQ ID NO:46的LCVR氨基酸序列;
e.SEQ ID NO:11的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:12的CDR1、CDR2和CDR3氨基酸序列;以及SEQ ID NO:40的HCVR氨基酸序列和SEQ ID NO:51的LCVR氨基酸序列;
f.SEQ ID NO:11的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:12的CDR1、CDR2和CDR3氨基酸序列;以及SEQ ID NO:41的HCVR氨基酸序列和SEQ ID NO:51的LCVR氨基酸序列;
g.SEQ ID NO:11的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:12的CDR1、CDR2和CDR3氨基酸序列;以及SEQ ID NO:42的HCVR氨基酸序列和SEQ ID NO:49的LCVR氨基酸序列;
h.SEQ ID NO:11的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:12的CDR1、CDR2和CDR3氨基酸序列;以及SEQ ID NO:43的HCVR氨基酸序列和SEQ ID NO:50的LCVR氨基酸序列;
i.SEQ ID NO:5的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:6的CDR1、CDR2和CDR3氨基酸序列;以及SEQ ID NO:38的HCVR氨基酸序列和SEQ ID NO:47的LCVR氨基酸序列;
j.SEQ ID NO:5的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:6的CDR1、CDR2和CDR3氨基酸序列;以及SEQID NO:39的HCVR氨基酸序列和SEQ ID NO:47的LCVR氨基酸序列;以及
k.SEQ ID NO:5的CDR1、CDR2和CDR3氨基酸序列和SEQ ID NO:6的CDR1、CDR2和CDR3氨基酸序列;以及SEQ ID NO:39的HCVR氨基酸序列和SEQ ID NO:48的LCVR氨基酸序列。
4.根据权利要求1至3中任一项所述的抗体,其中所述抗体包含在重链框架区或轻链框架区中的位置处的至少一个工程化半胱氨酸。
5.根据权利要求4所述的抗体,其中所述至少一个工程化半胱氨酸存在于所述抗体的选自重链40、41和89位(根据Kabat编号)以及轻链40和41位(根据Kabat编号)的一个或更多个位置处。
6.抗体-药物缀合物,其包含根据权利要求1至5中任一项所述的抗体。
7.根据权利要求6所述的抗体-药物缀合物,其包含根据权利要求4或5所述的抗体,其中接头药物通过所述至少一个工程化半胱氨酸与所述抗体位点特异性地缀合。
8.根据权利要求6或7所述的抗体-药物缀合物,其具有式(I)
其中,
n为0至3,
m代表1至6的平均DAR,
R1选自
y为1至16,并且
R2选自
9.根据权利要求8所述的抗体-药物缀合物,其中
n为0至1,
m代表1.5至2的平均DAR,
R1是
y为1至4,并且
R2选自
10.根据权利要求6至9中任一项所述的抗体-药物缀合物,其具有式(II)
11.根据权利要求6至10中任一项所述的抗体-药物缀合物,其中所述抗5T4抗体是包含选自以下的HCVR和LCVR的人源化抗体:
a.SEQ ID NO:61的HCVR氨基酸序列和SEQ ID NO:51的LCVR氨基酸序列;
b.SEQ ID NO:62的HCVR氨基酸序列和SEQ ID NO:51的LCVR氨基酸序列;
c.SEQ ID NO:63的HCVR氨基酸序列和SEQ ID NO:49的LCVR氨基酸序列;
d.SEQ ID NO:64的HCVR氨基酸序列和SEQ ID NO:50的LCVR氨基酸序列;
e.SEQ ID NO:59的HCVR氨基酸序列和SEQ ID NO:47的LCVR氨基酸序列;以及
f.SEQ ID NO:60的HCVR氨基酸序列和SEQ ID NO:48的LCVR氨基酸序列;
其中所述接头药物通过在重链第41位的工程化半胱氨酸与所述抗5T4抗体位点特异性地缀合。
12.药物组合物,其包含根据权利要求1至5中任一项所述的抗体或根据权利要求6至11中任一项所述的抗体-药物缀合物以及一种或更多种可药用赋形剂,所述药物组合物优选为冻干粉末的形式。
13.根据权利要求1至5中任一项所述的抗体、根据权利要求6至11中任一项所述的抗体-药物缀合物或根据权利要求12所述的药物组合物,其用作药物。
14.根据权利要求13所述的抗体、抗体-药物缀合物或药物组合物,其用于治疗人实体瘤和恶性血液病。
15.根据权利要求14所述应用的抗体、抗体-药物缀合物或药物组合物,其中所述人实体瘤选自:乳腺癌、胃癌、结直肠癌、卵巢癌、肺癌和间皮瘤。
16.根据权利要求1至5中任一项所述的抗体、根据权利要求6至11中任一项所述的抗体-药物缀合物或根据权利要求12所述的药物组合物与针对5T4抗原以外的癌症相关靶标的治疗性抗体、化学治疗剂和/或ADC的组合,其用于治疗人实体瘤和恶性血液病。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15195978 | 2015-11-24 | ||
EP15195978.0 | 2015-11-24 | ||
EP16191272.0 | 2016-09-29 | ||
EP16191272 | 2016-09-29 | ||
PCT/EP2016/078642 WO2017089447A1 (en) | 2015-11-24 | 2016-11-24 | Anti-5t4 antibodies and antibody-drug conjugates |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108348608A true CN108348608A (zh) | 2018-07-31 |
CN108348608B CN108348608B (zh) | 2022-02-08 |
Family
ID=57406227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680067751.2A Active CN108348608B (zh) | 2015-11-24 | 2016-11-24 | 抗5t4抗体和抗体-药物缀合物 |
Country Status (23)
Country | Link |
---|---|
US (2) | US11008400B2 (zh) |
EP (1) | EP3380122B1 (zh) |
JP (1) | JP6914956B2 (zh) |
KR (1) | KR20180083425A (zh) |
CN (1) | CN108348608B (zh) |
AU (1) | AU2016358854B2 (zh) |
BR (1) | BR112018010394A8 (zh) |
CA (1) | CA3005294A1 (zh) |
CL (1) | CL2018001334A1 (zh) |
CY (1) | CY1124456T1 (zh) |
DK (1) | DK3380122T3 (zh) |
ES (1) | ES2889398T3 (zh) |
HR (1) | HRP20211280T1 (zh) |
HU (1) | HUE055482T2 (zh) |
LT (1) | LT3380122T (zh) |
MX (1) | MX2018006372A (zh) |
MY (1) | MY187325A (zh) |
PL (1) | PL3380122T3 (zh) |
RU (1) | RU2736720C2 (zh) |
SG (1) | SG11201803692PA (zh) |
TW (1) | TWI744261B (zh) |
WO (1) | WO2017089447A1 (zh) |
ZA (1) | ZA201802584B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111499746A (zh) * | 2020-04-28 | 2020-08-07 | 优睿赛思(武汉)生物科技有限公司 | 一种针对人白介素-2的高亲和力兔单克隆抗体及其应用 |
CN111675762A (zh) * | 2019-03-11 | 2020-09-18 | 凯惠科技发展(上海)有限公司 | 一种含半胱氨酸的抗体、药物偶联物及其应用 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110831976A (zh) * | 2017-05-23 | 2020-02-21 | 斯索恩生物制药有限公司 | 用于制备抗体-药物缀合物的双重缀合方法 |
US11161897B2 (en) | 2017-07-17 | 2021-11-02 | Janssen Biotech, Inc. | Antigen binding regions against fibronectin type III domains and methods of using the same |
CN108187065B (zh) * | 2017-12-29 | 2023-04-28 | 广东众生药业股份有限公司 | 抗5t4抗体与美登素衍生物dm4偶联复合物及制备方法和用途 |
BR112020018490A2 (pt) | 2018-03-12 | 2020-12-29 | Genmab A/S | Anticorpo, imunoconjugado ou conjugado de anticorpo-fármaco, construção de ácido nucléico, vetor de expressão, célula, composição, composição farmacêutica, anticorpo, método, método para produzir um anticorpo, kit de partes, e, anticorpo anti-idiotípico |
WO2023155925A1 (en) * | 2022-02-21 | 2023-08-24 | Concept To Medicine Biotech Co., Ltd. | Anti-5t4 antibodies and uses thereof |
WO2024083953A1 (en) * | 2022-10-18 | 2024-04-25 | Tubulis Gmbh | Novel anti-tpbg antibody and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101437850A (zh) * | 2006-03-10 | 2009-05-20 | 惠氏公司 | 抗5t4抗体及其用途 |
WO2011133039A2 (en) * | 2010-04-21 | 2011-10-27 | Syntarga B.V. | Novel conjugates of cc-1065 analogs and bifunctional linkers |
WO2015155345A1 (en) * | 2014-04-11 | 2015-10-15 | Medimmune Limited | Antibodies and antibody-drug conjugates |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989007947A1 (en) | 1988-03-04 | 1989-09-08 | Cancer Research Campaign Technology Limited | Improvements relating to antigens |
GB0126378D0 (en) * | 2001-11-02 | 2002-01-02 | Oxford Biomedica Ltd | Antigen |
WO2005084390A2 (en) | 2004-03-02 | 2005-09-15 | Seattle Genetics, Inc. | Partially loaded antibodies and methods of their conjugation |
WO2006031653A2 (en) | 2004-09-10 | 2006-03-23 | Wyeth | Humanized anti-5t4 antibodies and anti-5t4 antibody / calicheamicin conjugates |
CA2580141C (en) * | 2004-09-23 | 2013-12-10 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
MX342860B (es) * | 2011-04-01 | 2016-10-14 | Wyeth Llc | Conjugados de anticuerpo-fármaco. |
DK3151865T3 (da) * | 2014-05-22 | 2021-10-25 | Byondis Bv | Stedsspecifik konjugation af linker medicin til antistof og resulterende adcs |
WO2017068687A1 (ja) * | 2015-10-22 | 2017-04-27 | 株式会社小松製作所 | 履帯リンクおよびリンク取付体 |
CN110831976A (zh) * | 2017-05-23 | 2020-02-21 | 斯索恩生物制药有限公司 | 用于制备抗体-药物缀合物的双重缀合方法 |
-
2016
- 2016-11-24 MY MYPI2018000802A patent/MY187325A/en unknown
- 2016-11-24 KR KR1020187017905A patent/KR20180083425A/ko active Search and Examination
- 2016-11-24 ES ES16801753T patent/ES2889398T3/es active Active
- 2016-11-24 AU AU2016358854A patent/AU2016358854B2/en not_active Ceased
- 2016-11-24 WO PCT/EP2016/078642 patent/WO2017089447A1/en active Application Filing
- 2016-11-24 BR BR112018010394A patent/BR112018010394A8/pt active Search and Examination
- 2016-11-24 EP EP16801753.1A patent/EP3380122B1/en active Active
- 2016-11-24 CA CA3005294A patent/CA3005294A1/en active Pending
- 2016-11-24 MX MX2018006372A patent/MX2018006372A/es unknown
- 2016-11-24 TW TW105138698A patent/TWI744261B/zh active
- 2016-11-24 PL PL16801753T patent/PL3380122T3/pl unknown
- 2016-11-24 US US15/778,759 patent/US11008400B2/en active Active
- 2016-11-24 SG SG11201803692PA patent/SG11201803692PA/en unknown
- 2016-11-24 HU HUE16801753A patent/HUE055482T2/hu unknown
- 2016-11-24 JP JP2018545692A patent/JP6914956B2/ja active Active
- 2016-11-24 RU RU2018122629A patent/RU2736720C2/ru active
- 2016-11-24 LT LTEPPCT/EP2016/078642T patent/LT3380122T/lt unknown
- 2016-11-24 CN CN201680067751.2A patent/CN108348608B/zh active Active
- 2016-11-24 DK DK16801753.1T patent/DK3380122T3/da active
-
2018
- 2018-04-18 ZA ZA2018/02584A patent/ZA201802584B/en unknown
- 2018-05-17 CL CL2018001334A patent/CL2018001334A1/es unknown
-
2021
- 2021-04-13 US US17/229,483 patent/US11584801B2/en active Active
- 2021-08-09 HR HRP20211280TT patent/HRP20211280T1/hr unknown
- 2021-08-25 CY CY20211100758T patent/CY1124456T1/el unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101437850A (zh) * | 2006-03-10 | 2009-05-20 | 惠氏公司 | 抗5t4抗体及其用途 |
WO2011133039A2 (en) * | 2010-04-21 | 2011-10-27 | Syntarga B.V. | Novel conjugates of cc-1065 analogs and bifunctional linkers |
WO2015155345A1 (en) * | 2014-04-11 | 2015-10-15 | Medimmune Limited | Antibodies and antibody-drug conjugates |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111675762A (zh) * | 2019-03-11 | 2020-09-18 | 凯惠科技发展(上海)有限公司 | 一种含半胱氨酸的抗体、药物偶联物及其应用 |
CN111675762B (zh) * | 2019-03-11 | 2023-12-01 | 凯惠科技发展(上海)有限公司 | 一种含半胱氨酸的抗体、药物偶联物及其应用 |
CN111499746A (zh) * | 2020-04-28 | 2020-08-07 | 优睿赛思(武汉)生物科技有限公司 | 一种针对人白介素-2的高亲和力兔单克隆抗体及其应用 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108348608A (zh) | 抗5t4抗体和抗体-药物缀合物 | |
KR102419766B1 (ko) | 항체에 대한 링커 약물의 부위 특이적 접합 및 그 결과로 얻어지는 adc | |
ES2814227T3 (es) | Anticuerpos anti-CD123 y conjugados de los mismos | |
BR112021004829A2 (pt) | conjugado de anticorpo anti-b7h3-análogo de exatecano e uso medicinal do mesmo | |
ES2879799T3 (es) | Anticuerpo anti-HER2 y conjugado del mismo | |
BR112019018541A2 (pt) | anticorpos cd147, anticorpos cd147 ativáveis e métodos de produção e uso dos mesmos | |
CN108848669A (zh) | Ror1抗体组合物和相关方法 | |
CN106459200A (zh) | 抗‑egfr抗体及抗体药物偶联物 | |
CN108136015A (zh) | 抗dll3抗体药物缀合物以及使用方法 | |
CN104341504A (zh) | 双特异性抗体 | |
CN108101825A (zh) | 用于抗体-药物偶联的双取代马来酰胺类连接子及其制备方法和用途 | |
CN108473588A (zh) | 新颖抗密封蛋白抗体及使用方法 | |
CN108430516A (zh) | 新颖抗emr2抗体和使用方法 | |
BR112020018618A2 (pt) | Conjugados anticorpo anti-her2 biparatópico-droga e métodos de uso | |
KR20240004708A (ko) | 넥틴-4 (nectin-4)를 표적하는 항체-약물 접합체 (antibody-drug conjugate) 및 이의 제조 방법 및 용도 | |
US20240226318A1 (en) | Antibody drug conjugate targeting nectin 4 and preparation method therefor and use thereof | |
US20220111008A1 (en) | Use of il-15 protein complex joint pd-l1 antibody for treating tumor diseases | |
Steiner | Targeted delivery of cytotoxic agents: direct conjugation to antibodies and pretargeting approaches | |
CA3236952A1 (en) | Antibody-drug conjugates against the receptor tyrosine kinase epha5 | |
BR112016026744B1 (pt) | Composto de conjugado anticorpo-droga, e, composição farmacêutica. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: Nijmegen Applicant after: Byodes Private Limited Address before: Nijmegen Applicant before: SYNTHON BIOPHARMACEUTICALS B.V. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |